ESA Treatment Shows Survival Benefit in Lower-Risk Myelodysplastic Syndromes
核心洞察
A large European registry study of 2,448 patients with lower-risk myelodysplastic syndromes (搜索) found that erythropoiesis (搜索)-stimulating agent treatment was associated with a 10.1-month improvement in median overall survival compared to no ESA (搜索) treatment.
ESA (搜索)-exposed patients demonstrated significantly better health-related quality of life, particularly when red blood cell transfusions were avoided, with quality of life remaining stable over time in this group.
The phase 3 EPO-PRETAR trial revealed that early initiation of ESA (搜索) therapy resulted in higher response rates and longer durations of transfusion independence compared to late initiation, despite similar time to transfusion dependence.
A comprehensive European registry study has demonstrated that erythropoiesis (搜索)-stimulating agent (ESA (搜索)) treatment significantly improves overall survival in patients with lower-risk myelodysplastic syndromes (搜索) (LR-MDS), providing new evidence for early intervention strategies in this patient population.
Registry Study Reveals Survival Advantage
The observational study, published in The Lancet Haematology and utilizing data from the European MDS (EUMDS (搜索)) registry, analyzed 2,448 patients with lower-risk MDS across 16 European countries and Israel. After propensity matching, researchers compared 744 ESA (搜索)-exposed patients with 426 ESA-unexposed patients.
At a median follow-up of 3.9 years, the ESA (搜索)-exposed cohort achieved a median overall survival of 44.9 months compared to 34.8 months in the ESA-unexposed group—an absolute difference of 10.1 months (HR, 0.70; 95% CI, 0.59-0.83; P < .0001).
"ESA (搜索) exposure appears to provide a benefit for patients with lower-risk myelodysplastic syndromes (搜索) by significantly delaying the onset of permanent transfusion dependency," the study authors concluded. "Moreover, ESA exposure was also associated with improved overall survival and quality of life."
Quality of Life Benefits Demonstrated
The study revealed significant quality-of-life improvements among patients who avoided red blood cell transfusions, regardless of ESA (搜索) exposure status. Using EQ-5D-3L and Visual Analog Scale responses, researchers found that health-related quality of life was significantly better among patients without transfusion requirements.
Importantly, quality of life did not deteriorate over time among ESA (搜索)-treated patients who avoided transfusions, with the red blood cell transfusion coefficient showing -0.04 (95% CI, -0.06 to 0.03; P < .0001) in the EQ-5D-3L index score model.
Timing of ESA Initiation Matters
Complementary findings from the phase 3 EPO-PRETAR trial examined the optimal timing of ESA (搜索) initiation in LR-MDS patients with anemia (搜索). The trial randomly assigned patients to receive ESA therapy either early—when hemoglobin levels were relatively high—or later, once hemoglobin approached transfusion thresholds. Both groups received identical dosing regimens of 60,000 units weekly for 12 weeks.
While time to transfusion dependence remained similar between groups, early ESA (搜索) initiation resulted in significantly higher response rates and longer durations of transfusion independence. The trial's primary endpoint was time to red blood cell transfusion dependence, with secondary endpoints including response rates and duration of transfusion independence.
Clinical Implications and Future Directions
The registry study authors noted that a prospective placebo-controlled trial designed to assess long-term survival in lower-risk MDS patients is unlikely to be performed, making their observational data particularly valuable for clinical decision-making.
"The clinical implication of this study is that ESA (搜索) treatment should be recommended at the onset of or early after the start of symptomatic anemia (搜索) with or without transfusions," the researchers stated. They emphasized that these findings may impact policies and clinical practice in countries without ESA access or where reimbursement only covers ESAs after patients require regular transfusions.
The study cohort included 62.1% male and 37.9% female patients, all diagnosed with International Prognostic Scoring System low or intermediate-1 risk MDS before July 1, 2019. ESAs are currently recommended by several guidelines as first-line therapy for anemia (搜索) in MDS patients.
Study Limitations and Strengths
While the registry study was limited by its observational design rather than being a prospective randomized placebo-controlled trial, the authors noted that the patient variation included is more representative of real-world clinical practice. Given that ESA (搜索) treatment has been in use for more than 30 years, propensity scoring provided a well-established method to account for between-group differences.
The researchers emphasized that neither this large registry analysis nor previous phase 2 or phase 3 trials have identified safety concerns with ESA (搜索) treatment, supporting its continued use in appropriate patient populations.